Norwalk Leslie V 4
4 · NEUROCRINE BIOSCIENCES INC · Filed Dec 17, 2025
Insider Transaction Report
Form 4
Norwalk Leslie V
Director
Transactions
- Exercise/Conversion
Common Stock
2025-12-15$92.35/sh+8,276$764,289→ 10,705 total - Exercise/Conversion
Common Stock
2025-12-15$84.95/sh+1,724$146,454→ 12,429 total - Sale
Common Stock
2025-12-15$152.23/sh−5,000$761,144→ 7,429 total - Sale
Common Stock
2025-12-16$155.09/sh−1,190$184,558→ 6,239 total - Exercise/Conversion
Non-Qualified Stock Option
2025-12-15−8,276→ 557 totalExercise: $92.35Exp: 2031-05-19→ Common Stock (8,276 underlying) - Exercise/Conversion
Non-Qualified Stock Option
2025-12-15−1,724→ 0 totalExercise: $84.95Exp: 2032-05-18→ Common Stock (1,724 underlying)
Footnotes (5)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.79 to $152.82. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $155.09 to $155.40. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F4]The option was granted on May 19, 2021 and vested in 12 equal monthly installments beginning June 19, 2021.
- [F5]The option was granted on May 18, 2022 and vested in 12 equal monthly installments beginning June 18, 2022.